No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
142 |
4. Check minimum number of eventsNone |
142 |
5. Include endpointsNone |
142 |
6. Filter based on genotype QC (FinnGen only) |
139 |
Control definitions (FinnGen only)
- Control exclude
- M13_SOFTTISSUE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other fibroblastic disorders
based on the number of shared cases.
Similar with more cases:
- Fibroblastic disorders
- Soft tissue disorders
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1061 | 528 | 526 |
| Only index persons | 957 | 489 | 468 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 51.89 | 50.70 | 52.89 |
| Only index persons | 50.79 | 49.57 | 52.07 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 139 | 71 | 68 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 51.04 | 47.99 | 54.23 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 142
- Matched controls
- 1420
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M72.9
ICD-10 Finland
Fibroblastic disorder, unspecified
+∞
77.3
67
*
M72.8
ICD-10 Finland
Other fibroblastic disorders
+∞
45.3
41
*
7287X
ICD-9 Finland
Disorders of muscle, ligament and fascia, Other fibromatoses[FIBROMATOSIS ALIA MUSCULI,LIGAMENTI ET FASCIAE]
+∞
40.6
37
*
NDM10
NOMESCO Finland
Palmar fasciotomy of hand
+∞
32.6
30
*
M72.0
ICD-10 Finland
Palmar fascial fibromatosis [Dupuytren]
110.6
32.4
34
*
M72.2
ICD-10 Finland
Plantar fascial fibromatosis
10.5
23.6
29
34
M79.6
ICD-10 Finland
Pain in limb
4.1
15.5
74
299
N03AX12
ATC
[U] gabapentin; oral
4.5
12.3
36
100
M75.1
ICD-10 Finland
Rotator cuff syndrome
4.0
10.8
37
115
G72.9
ICD-10 Finland
Myopathy, unspecified
118.4
10.6
11
*
9476
FHL
Splitting of fascia or aponeurosis
+∞
10.5
10
*
NHM10
NOMESCO Finland
Fasciotomy of ankle or foot
95.5
8.5
9
*
M01AX17
ATC
nimesulide; oral
3.0
8.0
45
189
ZXA05
NOMESCO Finland
Left side
3.1
7.9
43
177
N02AX02
ATC
tramadol; systemic, rectal
2.7
7.6
67
356
X59
ICD-10 Finland
Exposure to unspecified factor
3.2
7.2
34
128
N06AA09
ATC
amitriptyline; systemic
4.2
7.2
21
57
M25.5
ICD-10 Finland
Pain in joint
2.8
7.2
50
234
ZXE00
NOMESCO Finland
One hour or less
2.6
7.1
63
332
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.5
6.9
71
401
QCB10
NOMESCO Finland
Major dressing of wound of skin of upper limb
17.8
6.8
10
6
L17
ICPC
Foot/toe symptom/complaint
2.7
6.8
47
219
ZXE10
NOMESCO Finland
More than one and less than three hours
2.5
6.6
60
318
R22.4
ICD-10 Finland
Localized swelling, mass and lump, lower limb
15.2
6.5
10
7
N03AX16
ATC
[U] pregabalin
2.8
6.4
38
162
N06AX21
ATC
duloxetine; oral
3.8
6.3
20
58
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
6.1
48
236
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
20
90
2.42
2.97
5.0
2.8
3.43
1.96
mmol/l
0.59
15
74
39
232
1.94
2.90
2.3
1.8
2.88
3.27
mg/l
0.60
31
194
11
37
3.14
2.55
1.3
1.5
—
—
—
0
0
71
524
1.71
2.53
4.6
3.3
0.00
0.00
estimate
-0.00
17
108
70
517
1.70
2.47
4.7
3.2
0.00
0.00
estimate
-0.00
18
120
23
120
2.09
2.43
1.4
2.2
1.46
1.48
%
0.07
18
104
70
521
1.68
2.38
5.9
4.4
0.00
0.00
estimate
-0.00
16
112
28
159
1.95
2.35
1.4
1.2
25.24
43.90
iu/ml
0.79
15
64
69
513
1.67
2.34
6.8
7.9
1.22
1.22
mmol/l
0.08
58
435
6
13
4.77
2.29
1.0
1.2
—
—
—
0
0
80
625
1.64
2.19
4.1
5.4
6.90
6.68
mmol/l
0.31
70
588
63
464
1.64
2.18
6.5
6.7
1.21
1.22
mmol/l
0.12
57
426
98
807
1.69
2.18
4.5
3.6
14.72
11.46
mm/h
0.72
92
746
7
19
3.82
2.18
1.4
1.1
—
—
—
0
0
7
19
3.82
2.18
1.4
1.1
—
—
—
0
0
7
19
3.82
2.18
2.1
2.6
57.43
56.63
%
—
7
19
80
628
1.63
2.13
8.0
10.6
4.53
4.02
e9/l
0.86
69
558
36
230
1.76
2.09
1.6
1.5
0.82
1.13
mg/l
0.69
21
182
26
150
1.90
2.09
1.1
1.2
2.41
19.89
u/ml
—
9
62
34
214
1.77
2.08
1.3
1.2
0.68
0.78
u/ml
—
6
60
25
143
1.91
2.06
2.9
2.0
2.51
2.37
g/l
0.72
25
130
13
57
2.41
2.04
4.5
5.1
25.90
25.15
mmol/l
0.23
13
57
26
153
1.86
1.97
2.9
2.0
10.24
13.70
umol/l
1.83
26
145
102
861
1.66
1.94
6.6
7.5
77.55
79.32
u/l
0.23
95
808
118
1040
1.80
1.85
4.9
4.4
1.96
1.95
mu/l
0.03
111
950
29
180
1.77
1.85
2.8
3.4
2.45
2.45
mmol/l
0.00
23
157
41
282
1.64
1.81
4.3
3.5
0.00
0.01
estimate
0.50
15
113
23
136
1.82
1.72
3.1
2.0
15.80
23.35
%
2.56
23
120
54
403
1.55
1.68
2.3
1.9
101.01
98.38
pmol/l
0.11
29
182
10
42
2.48
1.65
2.1
1.8
—
—
—
0
0
8
32
2.59
1.62
2.3
1.6
—
—
—
0
0
7
26
2.78
1.60
1.7
1.3
—
—
—
0
0
10
44
2.37
1.59
1.0
1.0
—
—
—
0
0
38
266
1.59
1.55
2.5
2.8
347.85
11255.12
umol/l
2.26
33
230
11
51
2.25
1.55
3.2
2.0
0.75
0.67
%
0.33
11
51
55
419
1.51
1.54
4.1
3.3
—
—
—
0
0
6
21
2.94
1.52
1.2
1.2
—
—
—
0
0
25
159
1.69
1.47
2.0
1.8
—
—
—
0
0
18
104
1.84
1.45
3.6
3.7
—
—
—
0
0
12
60
2.09
1.43
6.6
8.5
90.22
92.52
%
0.35
12
60
28
189
1.60
1.32
1.6
1.7
1043.33
1244.32
nmol/l
0.72
21
132
18
108
1.76
1.29
1.9
1.7
—
—
—
0
0
34
242
1.53
1.28
2.7
2.3
—
—
—
0
0
6
25
2.46
1.25
1.2
1.5
—
—
—
0
0
23
152
1.61
1.18
1.5
1.4
—
—
—
0
0
18
112
1.70
1.15
1.8
1.6
—
—
—
0
0
37
277
1.45
1.09
2.0
3.3
3975.74
1278.02
ng/l
0.55
31
232
10
52
1.99
1.09
3.3
2.0
1.15
1.21
%
—
10
52
7
33
2.18
1.07
1.6
1.3
—
—
—
0
0
11
60
1.90
1.06
5.8
8.5
0.55
0.73
%
0.54
11
60
28
200
1.50
1.04
4.9
3.2
1248.64
118.16
ng/l
0.58
22
162
0
28
0.00
0.99
0.0
1.7
—
—
—
0
0
6
27
2.27
0.94
2.0
1.5
—
—
—
0
0
53
433
1.36
0.94
3.5
2.3
94.63
129.66
ug/l
1.38
47
393
95
850
1.36
0.91
4.0
3.7
14.88
14.91
pmol/l
0.03
88
768
121
1129
1.49
0.88
18.5
12.8
22.61
23.32
mg/l
0.08
93
867
57
478
1.32
0.84
2.7
2.6
—
—
—
0
0
13
82
1.64
0.81
1.5
2.0
—
—
—
0
0
6
33
1.85
0.80
1.7
2.0
—
—
—
0
0
6
33
1.85
0.80
1.8
1.2
0.17
0.23
g/l
—
6
28
45
367
1.33
0.80
2.2
3.3
2.34
2.35
mmol/l
0.07
37
331
11
67
1.70
0.77
1.3
1.3
—
—
—
0
0
6
34
1.80
0.77
1.2
5.4
—
1.00
—
0
5
58
494
1.29
0.75
15.3
11.7
1.08
1.21
inr
0.67
20
158
40
324
1.33
0.74
3.8
3.6
7.22
10.65
mg/mmol
0.36
29
203
38
306
1.33
0.73
3.8
2.5
0.17
0.42
e6/l
1.36
32
226
5
26
1.96
0.71
1.4
1.7
55.60
71.23
pmol/l
—
5
26
5
26
1.96
0.71
1.2
1.2
—
—
—
0
0
7
41
1.74
0.71
1.7
2.2
0.36
0.94
ug/l
—
7
34
36
289
1.33
0.71
1.6
1.7
1.47
1.40
mmol/l
0.14
27
245
10
61
1.69
0.70
5.7
8.2
1.31
1.66
%
—
10
61
21
154
1.43
0.70
4.4
2.4
3.09
2.20
e6/l
0.28
13
82
11
72
1.57
0.61
2.4
2.4
63.33
56.96
ml/min/173m2
—
6
26
6
35
1.75
0.58
1.0
1.2
—
—
—
0
0
13
90
1.49
0.58
1.6
2.1
—
—
—
0
0
6
37
1.65
0.56
2.2
2.6
—
—
—
0
0
9
64
1.43
0.52
7.1
3.7
3.51
2.39
mmol/l
—
9
51
6
40
1.52
0.52
2.3
2.2
—
—
—
0
0
22
173
1.32
0.50
4.2
2.2
1.51
1.27
e6/l
0.18
14
100
44
380
1.23
0.49
4.0
2.7
—
—
—
0
0
48
419
1.22
0.48
3.4
3.4
44.24
27.76
ng/l
0.32
34
276
133
1292
1.46
0.46
26.3
19.0
39.54
40.79
%
1.11
125
1210
10
69
1.48
0.45
6.3
2.6
109.90
70.53
ng/l
—
10
64
75
689
1.19
0.43
3.0
2.8
—
—
—
0
0
117
1120
1.25
0.42
4.9
4.4
6.19
5.99
mmol/l
0.81
111
1022
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
5
36
1.40
0.38
1.2
1.8
—
—
—
0
0
10
72
1.42
0.38
1.6
1.6
—
—
—
0
0
16
126
1.30
0.37
6.3
6.4
100.56
104.47
mmol/l
2.51
16
126
133
1295
1.43
0.37
26.7
19.0
135.03
137.06
g/l
0.77
133
1270
114
1102
1.17
0.27
16.2
11.6
83.91
81.58
ml/min/173m2
0.63
95
912
5
38
1.33
0.23
1.0
1.4
42.80
39.82
nmol/l
—
5
38
42
385
1.13
0.22
4.0
4.4
1.86
2.90
ug/l
0.62
36
347
5
42
1.20
0.21
2.2
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
13.09
—
0
11
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
61
578
1.10
0.18
4.1
6.5
9.52
11.23
umol/l
1.32
56
549
7
62
1.14
0.17
2.7
2.8
26.43
24.64
mmol/l
—
7
62
14
122
1.16
0.14
12.6
6.5
—
—
—
0
0
120
1178
1.12
0.14
4.9
4.8
2.75
2.80
mmol/l
0.28
114
1090
29
311
0.92
0.12
3.9
4.0
21.33
21.38
%
0.01
13
142
10
109
0.91
0.04
2.1
1.7
—
—
—
0
0
18
174
1.04
0.00
1.4
1.4
—
—
—
0
0
108
1078
1.01
0.00
6.7
5.5
41.11
40.00
mmol/mol
0.49
103
995
23
228
1.01
0.00
3.0
2.7
0.67
0.79
ug/l
0.35
13
143
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
4.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
218.20
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
8.27
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
92.20
—
0
5
0
7
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
11.74
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
2.71
—
0
7
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
40.00
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint M13_FIBROBLASTNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_FIBROBLASTNAS | 1.513 [1.07, 2.14] | 0.019 |
| Birth year | 0.992 [0.98, 1.0] | 0.059 |
During the follow-up period (1.1.1998 — 31.12.2019), 55 out of 333 females with M13_FIBROBLASTNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_FIBROBLASTNAS | 1.146 [0.9, 1.45] | 0.263 |
| Birth year | 0.993 [0.98, 1.0] | 0.158 |
During the follow-up period (1.1.1998 — 31.12.2019), 87 out of 384 males with M13_FIBROBLASTNAS died.
Mortality risk
Mortality risk for people of age
years, who have M13_FIBROBLASTNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.163% | 0.247% |
| 5 | 0.856% | 1.611% |
| 10 | 2.199% | 3.758% |
| 15 | 3.941% | 7.482% |
| 20 | 6.81% | 12.945% |
Relationships between endpoints
↥Index endpoint: M13_FIBROBLASTNAS – Other fibroblastic disorders
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data